



[Billing Code: 4140-01-P]

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

National Institute on Drug Abuse Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended

(5 U.S.C. App), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 USC, as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel
Mechanism for Time-Sensitive Drug Abuse Research (R21)

Date: March 16, 2017

Time: 12:30 PM to 3:00 PM

Agenda: To review and evaluate grant applications

Place: National Institutes of Health
Neuroscience Center
6001 Executive Boulevard
Rockville, MD 20852
(Telephone Conference Call)

Contact Person: Ivan K. Navarro, Ph.D.
Scientific Review Officer
Office of Extramural Policy and Review
Division of Extramural Research
National Institute on Drug Abuse, NIH, DHHS
6001 Executive Boulevard, Room 4242, MSC 9550
Bethesda, MD 20892
301-827-5833
ivan.navarro@nih.gov

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel
Identification of Genetic and Genomic Variants by Next-Gen
Sequencing in Non-human Animal Models (U01)

Date: March 23, 2017

Time: 11:00 AM to 3:00 PM

Agenda: To review and evaluate cooperative agreement applications

Place: National Institutes of Health
Neuroscience Center
6001 Executive Boulevard
Rockville, MD 20852
(Telephone Conference Call)

Contact Person: Shang-Yi Anne Tsai, Ph.D.
Scientific Review Officer
Office of Extramural Policy and Review
Division of Extramural Research
National Institute on Drug Abuse, NIH, DHHS
6001 Executive Boulevard, Room 4228, MSC 9550
Bethesda, MD 20892
301-827-5842
shangyi.tsai@nih.gov

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel
Extracellular Vesicle Tools, Technologies, and Products for
Neuroscience Research (R41/R42/R43/R44)

Date: March 24, 2017

Time: 2:00 PM to 8:00 PM

Agenda: To review and evaluate grant applications

Place: National Institutes of Health
Neuroscience Center
6001 Executive Boulevard
Rockville, MD 20852
(Virtual Meeting)

Contact Person: Susan O. McGuire, Ph.D.
Scientific Review Officer
Office of Extramural Policy and Review
National Institute on Drug Abuse
National Institutes of Health, DHHS
6001 Executive Blvd., Room 4245
Rockville, MD 20852
(301) 827-5817
mcguireso@mail.nih.gov

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel
Cutting-Edge Basic Research Awards (CEBRA) (R21)

Date: March 27, 2017

Time: 9:00 AM to 5:00 PM

Agenda: To review and evaluate grant applications

Place: Hilton Garden Inn Bethesda
7301 Waverly Street
Bethesda, MD 20814

Contact Person: Gerald L. McLaughlin, Ph.D.
Scientific Review Officer
Office of Extramural Policy and Review
National Institute on Drug Abuse, NIH, DHHS
6001 Executive Blvd., Room 4238, MSC 9550
Bethesda, MD 20892-9550
301-827-5819
gm145a@nih.gov

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel
Avenir Award Program for Genetics or Epigenetics of Substance Use
Disorders (DP1)

Date: April 7, 2017

Time: 8:00 AM to 6:00 PM

Agenda: To review and evaluate grant applications

Place: Courtyard by Marriott
5520 Wisconsin Avenue
Chevy Chase, MD 20815

Contact Person: Gerald L. McLaughlin, Ph.D.
Scientific Review Officer
Office of Extramural Policy and Review
National Institute on Drug Abuse, NIH, DHHS
6001 Executive Blvd., Room 4238, MSC 9550
Bethesda, MD 20892-9550
301-827-5819
gm145a@nih.gov

(Catalogue of Federal Domestic Assistance Program Nos.: 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS)

Dated: **February 24, 2017**

Natasha M. Copeland, Program Analyst
Office of Federal Advisory Committee Policy
[FR Doc. 2017-04026 Filed: 3/1/2017 8:45 am; Publication Date: 3/2/2017]